{"id":63169,"date":"2026-05-27T22:03:28","date_gmt":"2026-05-27T20:03:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/genomic-testing-cooperative-to-exhibit-and-present-research-at-2026-asco-annual-meeting\/"},"modified":"2026-05-27T22:03:28","modified_gmt":"2026-05-27T20:03:28","slug":"genomic-testing-cooperative-to-exhibit-and-present-research-at-2026-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/genomic-testing-cooperative-to-exhibit-and-present-research-at-2026-asco-annual-meeting\/","title":{"rendered":"Genomic Testing Cooperative to Exhibit and Present Research at 2026 ASCO Annual Meeting"},"content":{"rendered":"
\n

\nGTC will spotlight DNA and RNA-based precision oncology testing, liquid biopsy applications and research across hematologic malignancies, breast cancer metastasis and CNS involvement<\/i><\/p>\n

<\/a>
<\/a><\/p>\n

CHICAGO–(BUSINESS WIRE)–Genomic Testing Cooperative, a molecular diagnostics company advancing comprehensive cancer profiling through DNA and RNA analysis, will exhibit and present research at the 2026 American Society of Clinical Oncology Annual Meeting<\/a>. ASCO 2026 will bring together the global oncology community to explore high-impact cancer research, clinical advances, and new technologies shaping the future of cancer care. More than 3,400 abstracts are expected to be presented at this year\u2019s meeting.<\/p>\n

\nWHAT:<\/b><\/p>\n

\nGTC will be available throughout ASCO 2026 to connect with media, oncology leaders, industry analysts, financial analysts, pharmaceutical companies, cancer centers, laboratories and potential strategic partners interested in the company\u2019s comprehensive testing platform, cooperative business model and approach to precision cancer diagnostics.<\/p>\n

\nWHEN:<\/b><\/p>\n

\nMay 29 to June 2, 2026<\/p>\n

\nWHERE:<\/b><\/p>\n

\nMcCormick Place, Chicago \u2013 Booth #17146<\/p>\n

\nGTC PRESENTATIONS AND AFFILIATED POSTERS:<\/b><\/p>\n

\nDetails for each presentation are available at genomictestingcooperative.com\/asco2026\/<\/a>, and the posters will be posted here after ASCO.<\/p>\n\n\n\n\n\n\n\n\n
\n

\nSESSION<\/b><\/p>\n<\/td>\n

\n

\nTITLE<\/b><\/p>\n<\/td>\n

\n

\nDATE & TIME<\/b><\/p>\n<\/td>\n

\n

\nABSTRACT<\/b><\/p>\n<\/td>\n

\n

\nPOSTER BOARD<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nHematologic Malignancies, Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n<\/td>\n

\n

\nDefining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile<\/p>\n<\/td>\n

\n

\nJune 1, 2026,
\n
9 a.m. to noon CDT<\/p>\n<\/td>\n

\n

\n7075<\/p>\n<\/td>\n

\n

\n573<\/p>\n<\/td>\n<\/tr>\n

\n

\nBreast Cancer, Metastatic<\/p>\n<\/td>\n

\n

\nDominant chromosomal abnormalities in breast cancer metastasis to CNS, as compared with systemic metastasis, demonstrated by liquid biopsy<\/p>\n<\/td>\n

\n

\nJune 1, 2026,
\n
1:30-4:30 p.m. CDT<\/p>\n<\/td>\n

\n

\n1035<\/p>\n<\/td>\n

\n

\n149<\/p>\n<\/td>\n<\/tr>\n

\n

\nHematologic Malignancies, Leukemia, Myelodysplastic Syndromes and Allotransplant<\/p>\n<\/td>\n

\n

\nDistinction of FLT3-ITD transcriptomic signature from FLT3-TKD and the frequency of this signature in acute myeloid leukemia without FLT3 mutation<\/p>\n<\/td>\n

\n

\nJune 1, 2026,
\n
9 a.m.-noon CDT<\/p>\n<\/td>\n

\n

\n6538<\/p>\n<\/td>\n

\n

\n331<\/p>\n<\/td>\n<\/tr>\n

\n

\nDevelopmental Therapeutics, Molecularly Targeted Agents and Tumor Biology<\/p>\n<\/td>\n

\n

\nComprehensive profiling and clinical utility of CSF-derived cell-free DNA\/RNA for evaluation of solid and hematologic malignancies affecting the central nervous system<\/p>\n<\/td>\n

\n

\nMay 30, 2026<\/p>\n<\/td>\n

\n

\n3066<\/p>\n<\/td>\n

\n

\n203<\/p>\n<\/td>\n<\/tr>\n

\n

\nHematologic Malignancies, Leukemia, Myelodysplastic Syndromes and Allotransplant<\/p>\n<\/td>\n

\n

\nTP53 mutation adoption of stromal-adhesion\/neuronal-like programs as a driver of stress adaptation and acute myelogenous leukemia cell survival<\/p>\n<\/td>\n

\n

\nJune 1, 2026<\/p>\n<\/td>\n

\n

\n6545<\/p>\n<\/td>\n

\n

\n338<\/p>\n<\/td>\n<\/tr>\n

\n

\nHematologic Malignancies, Leukemia, Myelodysplastic Syndromes and Allotransplant<\/p>\n<\/td>\n

\n

\nA two-axis machine learning framework for cell-of-origin inference in AML: A proof-of-concept study<\/p>\n<\/td>\n

\n

\nJune 1, 2026<\/p>\n<\/td>\n

\n

\n6540<\/p>\n<\/td>\n

\n

\n333<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nMEDIA AND ANALYST OPPORTUNITIES<\/b><\/p>\n

\nMembers of the media, industry analysts and financial analysts may schedule meetings with GTC leadership to discuss:<\/p>\n